Ignite Creation Date:
2024-05-05 @ 12:01 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00212381
Status:
COMPLETED
Last Update Posted:
2017-03-29
First Post:
2005-09-13
Brief Title:
Oral Diindolylmethane DIM for the Treatment of Cervical Dysplasia
Sponsor:
New York Presbyterian Hospital
Organization:
New York Presbyterian Hospital
Study Overview
Official Title:
Diindolylmethane DIM Dietary Supplementation A Nonsurgical Treatment for Cervical Intraepithelial Neoplasia CIN
Status:
COMPLETED
Status Verified Date:
2017-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine if the use of oral Diindolylmethante DIM a marketed cruciferous vegetable based dietary supplement Bioresponse-DIM is associated with the regression of cervical dysplasia in otherwise healthy women
Detailed Description:
To determine if the use of oral Diindolylmethane DIM a marketed cruciferous vegetable based dietary supplement BioResponse-DIM is associated with the regression of cervical dysplasia in otherwise healthy women Additionally the study aims to see how the use of the BioResponse-DIM supplement correlates with cervical HPV colonization and to asses the tolerability of daily DIM supplementation
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None